Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA helicase B (HELB) is a conserved DNA-dependent ATPase and 5′–3′ DNA helicase in higher eukaryotes, particularly humans, where it plays essential roles in the initiation of DNA replication and the cellular responses to replication stress and DNA damage. HELB localizes to the nucleus in the G1 phase to participate in assembly of the replication pre-initiation complex via interactions with DNA polymerase α-primase, CDC45, and TOPBP1. Upon CDK2-mediated phosphorylation at the G1-S transition, HELB is exported to the cytosol but can relocalize to chromatin in response to replication stress or DNA damage. HELB contributes to genomic stability by promoting replication origin firing, stimulating RNA primer synthesis, and regulating homologous recombination through inhibition of long-range resection at DNA double-strand breaks. Dysregulation of HELB has been observed in some cancers, suggesting a role in tumorigenesis. Mutations in HELB or altered expression can compromise DNA replication and DNA repair fidelity, making it a potential biomarker for replication stress and therapeutic target in cancer biology[1][4][7][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA helicase B (HELB).